Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.